SCYNEXIS, Inc.

SCYNEXIS, Inc.

SCYX

NASDAQHealthcareMedical - Pharmaceuticals

GoAI で開く

最新データ

$4.08

−$0.14 · -3.32%

読み込み中

SCYXの企業概要

企業プロフィール

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.